Adjuvant SACT post surgery
Scottish Cancer Network: Clinical Management Pathways
Throughout the patient pathway, consideration should be given to patient preference, performance status and other relevant patient factors.
Patient eligibility and suitability for available clinical trials should be considered and discussed with individual patients as appropriate.
| Date of creation | 20/09/2023 | Version number | 1.0 |
| Author | Nicola Steele (on behalf of SACT subgroup) | Reviewer | John Maclay |
|
Updated |
23/07/2025 |
Version number | 1.2 |
| Author | Nicola Steele (on behalf of SACT subgroup) | Approval | Editorial Group |
| Description of last update |
23/07/2025 v1.2 2) Section: Resected NSCLC (EGFR WT) - No Prior Neo-adjuvant SACT
Pathway renamed "Resected NSCLC (ALK & EGFR WT) - No Prior Neo-adjuvant SACT". Minor adjustments made for clarity in light of added ALK translocation positive pathway
09/05/2024 v1.1 |
||
| Review Date | 20/09/2026 | Contact | |
The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.